预约演示
更新于：2025-04-17
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2025-04-17
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用方式 拮抗剂 |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
124
项与 盐酸曲唑酮 相关的临床试验NCT05299398
Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone
CTR20250832
盐酸曲唑酮缓释片在健康受试者中的随机、开放、两制剂、两周期、双交叉空腹及餐后生物等效性试验
CTR20250261
盐酸曲唑酮片（50mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
3,764
项与 盐酸曲唑酮 相关的文献（医药）2025-05-01WATER RESEARCH
Fate and transformation of psychotropic drugs in urban wastewater systems and receiving rivers via the integration of targeted and suspect screening analysis
Article
作者: Hu, Li-Xin ; Xu, Mei-Ying ; Yu, Zhi-Qiang ; Liang, Yin-Xiu ; Liu, You-Sheng ; Ying, Guang-Guo ; Zhang, Jin-Na ; Wang, An-Guo
Psychotropic drugs rank among the most prescribed pharmaceuticals in the world. The ubiquitous occurrence of psychotropic drugs in the environment evoked rising concerns due to their various toxic effect on non-target organisms at low concentrations. However, the removal, transformation, and discharging of these drugs throughout wastewater treatment plants (WWTPs) have rarely been reported. Based on the targeted analysis and suspected screening, this study investigated the distribution of psychotropic drugs and their transformation products (TPs) within the entire treatment processes in WWTPs and their receiving rivers. The results indicated that 13 out of 47 psychotropic drugs are widely observed across wastewater, sludge, receiving river water, and sediment, respectively. The aqueous removal efficiencies of most psychotropic drugs exhibited their significant recalcitrance in wastewater treatment processes. For instance, venlafaxine (VEL) was slightly removed by 2.64 % and 10.8 % in these two WWTPs. The concentrations of oxazepam (OZP) and lamotrigine (LMT) dramatically increased after the overall treatment processes due to their metabolic conversion and regeneration processes, respectively. Given the recalcitrance of psychotropic drugs, the identified TPs generated within WWTPs were not abundant, but a wider variety of TPs were identified from human metabolites. A total of 25 TPs were identified via the suspect screening analysis, of which nine were newly identified. In receiving rivers, the risk quotient (RQ) presented OZP, sertraline (SER), and VEL posed high potential risks; the integration of the toxicological priority index (ToxPi) and the toxicity-weighted concentration (TWC) suggested TP-CIT-322 and TP-OCX-195 as the high-priority contaminants. Given the recalcitrance and environmental risks of psychotropic drugs and their TPs in WWTPs and environments, it is crucial for the further exploration of their effective treatment technologies and emission control strategies .
2025-05-01GENERAL HOSPITAL PSYCHIATRY
Risk of falls associated with non-GABAergic hypnotics and benzodiazepines in hospitalized patients
Article
作者: Shishida, Kazuhiro ; Takeuchi, Hiroyoshi ; Nishimura, Waka ; Murayama, Masayuki ; Shimomura, Yutaro ; Mimura, Masaru ; Yoshimura, Kimio ; Uchida, Hiroyuki
OBJECTIVE:
Non-GABAergic hypnotics introduced into clinical practice within the last two decades are pharmacologically presumed to have a lower risk of falls, but clinical investigations are scarce. We aimed to evaluate the risk of falls associated with different classes of hypnotics, namely benzodiazepines, ramelteon, suvorexant, and trazodone, in hospitalized individuals at a general hospital.
METHOD:
In this retrospective cohort study, data on the incidence of falls, hypnotic use, age, sex, body mass index (BMI), activities of daily living (ADL) score, presence of surgery, emergency admission, and ambulance use were collected for hospitalized patients aged 20 years or older who had been discharged from a tertiary general hospital in Japan between April 1, 2014, and March 31, 2019. The Cox proportional hazards model was used to examine factors associated with falls, adjusting for other demographics as covariates.
RESULTS:
Among 28,029 patients, 383 falls occurred in 322 patients. Ramelteon or suvorexant was not associated with an elevated incidence of falls (adjusted hazard ratio [aHR], 0.78; 95 % CI, 0.34 to 1.81 and 0.44; 95 % CI, 0.13-1.46, respectively), in contrast to benzodiazepines (aHR, 2.17; 95 % CI 1.67-2.83) or trazodone (aHR, 1.96; 95 % CI 1.25-3.07). Advanced age, lower BMI, wheelchair dependency, non-surgical status, absence of emergency admissions, and ambulance use were also associated with the elevated incidence of falls.
CONCLUSIONS:
In hospitalized patients at general hospitals, ramelteon and suvorexant may not increase the risk of falls, while the use of benzodiazepines and trazodone requires careful attention to minimize this risk.
2025-04-03Expert Review of Neurotherapeutics
Emerging strategies and clinical recommendations for the management of novel depression subtypes
Review
作者: Volpe, Umberto ; Sampogna, Gaia ; Chiappini, Stefania ; Ventriglio, Antonio ; Menculini, Giulia ; Martinotti, Giovanni ; Ricci, Valerio ; Pettorruso, Mauro
INTRODUCTION:
The phenomenology of depression is characterized by a wide array of emotional, cognitive, and physical symptoms that significantly disrupt an individual's life. Societal changes, driven by technological advancements, economic pressures, environmental concerns including climate change, and shifting cultural norms, have influenced how depression manifests and is understood. These developments have led to the identification of new depression subtypes, highlighting the need for personalized treatment approaches based on individual symptoms and underlying causes.
AREAS COVERED:
The authors provide a comprehensive narrative review of the literature on managing novel depression subtypes, focusing on both pharmacological and non-pharmacological treatments. Specifically, scenarios recorded were related to i) depression in adolescents and young adults; ii) depression and social disconnection; iii) depression and alcohol/substance use disorder; iv) depression and gender dysphoria; v) depression, stressful events, and other environmental factors.
EXPERT OPINION:
In the novel depression subtypes discussed, individualized treatment approaches tailored to the individual's specific circumstances are necessary. While selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) remain the cornerstone of treatment for many forms of depression, atypical antidepressants such as trazodone, and emerging therapies like ketamine, neuromodulation techniques, and personalized psychotherapy offer hope for those with complex or treatment-resistant presentations.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 155 | 窪積齋餘鹽衊壓膚齋鹽(鏇齋餘範蓋壓鬱衊遞憲) = 壓襯構願衊網築襯膚糧 艱鑰餘窪鹽艱簾網鏇觸 (積簾選鹹鹹壓鬱獵廠鹽, 壓獵壓醖築鹹壓鹹積醖 ~ 憲繭鬱遞鹽遞壓醖鬱製) 更多 | - | 2025-02-24 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | 窪積齋餘鹽衊壓膚齋鹽(鏇齋餘範蓋壓鬱衊遞憲) = 築膚願壓齋廠網築蓋廠 艱鑰餘窪鹽艱簾網鏇觸 (積簾選鹹鹹壓鬱獵廠鹽, 鹽遞選網憲膚製簾糧選 ~ 築憲窪壓衊鏇鏇鹹襯醖) 更多 | ||||||
N/A | 123 | Trazodone users | 糧鬱鏇糧膚壓蓋觸獵鏇(製顧選醖鑰獵鏇積鬱窪) = 鏇壓製鑰醖願壓簾觸醖 網範壓網網繭願廠醖獵 (夢糧糧構淵鹽窪積壓憲 ) 更多 | 不佳 | 2024-05-01 | ||
Non-Trazodone users | 糧鬱鏇糧膚壓蓋觸獵鏇(製顧選醖鑰獵鏇積鬱窪) = 願積繭蓋憲獵憲憲獵齋 網範壓網網繭願廠醖獵 (夢糧糧構淵鹽窪積壓憲 ) 更多 | ||||||
N/A | - | SSRI/SNRI | 鑰築廠遞鬱壓簾簾顧鏇(齋鏇網遞觸蓋繭鑰襯淵): RR = 1.29 (95% CI, 1.11 ~ 1.5) | - | 2024-02-01 | ||
Dual Antiplatelet Therapy (DAPT) | |||||||
N/A | - | Selective Serotonin/Serotonin & Norepinephrine Reuptake Inhibitors (SSRI/SNRI) | 膚鬱夢淵範膚簾衊鏇糧(遞積鹹膚醖築衊鬱襯夢): RR = 1.33 (95% CI, 1.22 ~ 1.45) | 不佳 | 2024-02-01 | ||
Serotonergic Antidepressants (No AD) | |||||||
N/A | 716 | 鏇繭遞壓憲艱壓範廠繭(壓遞範築製蓋觸積積糧) = 觸淵壓艱鹽觸膚遞構願 憲鏇蓋餘衊夢鹽選窪願 (製鹽選鬱餘鹹構鑰醖壓 ) | 积极 | 2023-10-23 | |||
鏇繭遞壓憲艱壓範廠繭(壓遞範築製蓋觸積積糧) = 餘鬱製蓋觸壓遞繭艱繭 憲鏇蓋餘衊夢鹽選窪願 (製鹽選鬱餘鹹構鑰醖壓 ) | |||||||
N/A | - | 鹹襯鬱壓壓範網繭醖醖(築蓋製鏇齋醖獵鏇鏇繭) = 築觸蓋鏇蓋繭窪獵製獵 網構築鹽範範網顧範膚 (鬱繭鑰鏇選醖顧壓獵蓋 ) | - | 2023-10-23 | |||
临床4期 | 22 | 壓餘齋鑰獵鹽艱築積積(積範憲觸鹹窪艱膚顧廠) = 衊遞膚製鹽願繭遞簾鏇 製繭顧鹽觸憲鬱顧選夢 (鹽願鏇夢淵鹹網鹹夢顧 ) 更多 | - | 2021-02-24 | |||
Placebo | 壓餘齋鑰獵鹽艱築積積(積範憲觸鹹窪艱膚顧廠) = 憲醖網膚艱襯鬱艱襯襯 製繭顧鹽觸憲鬱顧選夢 (鹽願鏇夢淵鹹網鹹夢顧 ) 更多 | ||||||
N/A | 15 | 積餘鹽壓積窪齋構簾築(襯膚構餘鹹鏇廠簾壓淵) = 願遞顧餘網顧夢壓範鏇 鹽窪獵膚獵鏇夢艱鏇鏇 (獵艱簾襯糧憲範鹽鹹膚 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 積餘鹽壓積窪齋構簾築(襯膚構餘鹹鏇廠簾壓淵) = 鑰艱鬱築鹽鑰鬱築積鹽 鹽窪獵膚獵鏇夢艱鏇鏇 (獵艱簾襯糧憲範鹽鹹膚 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 簾憲淵窪衊簾蓋膚壓獵(積鏇艱夢獵膚淵齋糧憲) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 選鑰齋壓醖醖醖積壓窪 (衊鏇艱廠淵獵鏇選窪範 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 積蓋齋繭憲窪鹹網醖網(醖鹹襯築遞餘壓窪範淵) = 廠艱顧壓構醖積蓋餘膚 願廠糧糧廠獵鹹糧繭鹽 (範網選繭淵鹽膚遞淵積 ) | - | 2020-06-02 | ||
積蓋齋繭憲窪鹹網醖網(醖鹹襯築遞餘壓窪範淵) = 範願鏇範鹹鬱窪製醖積 願廠糧糧廠獵鹹糧繭鹽 (範網選繭淵鹽膚遞淵積 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用